ASH 2023 | Is HSCT a suitable treatment option for patients with ALL who have achieved undetectable BCR::ABL1?
Mark Litzow, MD, Mayo Clinic, Rochester, MN, comments on the role of hematopoietic stem cell transplantation (HSCT) in patients with acute lymphoblastic leukemia (ALL) who have attained undetectable BCR::ABL1 status. He notes that while there is still a benefit of HSCT in these patients, the necessity is diminished due to improved survival outcomes compared to those who are BCR::ABL1 positive. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen: Research Funding, Consultancy; Astellas: Research Funding; Novartis: Research Funding; Syndax: Research Funding; Jazz: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Actinium: Research Funding; Pluristem: Research Funding; Biosight: Consultancy, Other: Data Monitoring Board; Abbvie: Research Funding; Beigene: Consultancy.
